tiprankstipranks
BofA moves to No Rating on Pactiv Evergreen after Novolex deal
The Fly

BofA moves to No Rating on Pactiv Evergreen after Novolex deal

BofA analyst George Staphos moves to No Rating on Pactiv given the stock is no longer trading on fundamentals following Apollo-owned Novolex having announced that the two packaging companies will combine with Pactiv shareholders receiving $18 per share in cash. The firm believes the stock is no longer trading on the basis of fundamentals, the analyst tells investors.

Pick the best stocks and maximize your portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App